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ABSTRACT
Purpose To investigate the hypothesis that paracetamol is
absorbed faster from a hot drink than from a standard tablet using
simultaneous scintigraphic imaging and pharmacokinetic
sampling.
Methods Twenty-five healthy male volunteers received both
paracetamol formulations in a randomised manner. The formula-
tion administered in the first treatment arm was radiolabelled to
allow scintigraphic monitoring. In both treatment arms, blood
samples were taken for assessing paracetamol absorption.
Results Following the hot drink, paracetamol absorption was
both significantly faster and greater over the first 60 min post-
dose compared with the tablet, as evidenced by the median time
to reach t0.25μg/mL of 4.6 and 23.1 min, respectively, and AUC0-
60 of 4668.00 and 1331.17 h*ng/mL, respectively. In addition,
tmax was significantly shorter for the hot drink (median time =
1.50 h) compared with the tablet (1.99 h). However, Cmax was
significantly greater following the tablet (9,077 ng/mL) compared
with the hot drink (8,062 ng/mL). Onset of gastric emptying after
the hot drink was significantly faster than after the standard tablet
(7.9 versus 54.2 min), as confirmed scintigraphically.
Conclusions Compared with a standard tablet, a hot drink pro-
vides faster absorption of paracetamol potentially due to more
rapid gastric emptying.




ANOVA Analysis of variance
ARSAC Administration of radioactive substance
advisory committee
AUC Area under the curve
AUC0-30 Area under the concentration/time curve from
0 to 30 min
AUC0-60 Area under the concentration/time curve from
0 to 60 min
BMI Body mass index
CI Confidence interval
Cmax Maximum concentration
CRF Case Report Form
ECG Electrocardiogram
GCP Good clinical practice
GI Gastrointestinal
LLOQ Lower limit of quantification
PK Pharmacokinetic
SAE Serious adverse event
SAS Statistical analysis software
SD Standard deviation
t0.25 Time to reach 0.25mcg/mL
tmax Time at which Cmax is observed
99mTc DTPA Technetium-99 m diethylenetriamine
pentaacetic acid
INTRODUCTION
The common cold is one of the most frequent human illnesses
worldwide (1) and, although no cure exists, symptoms are
treatable. A plethora of cold remedies exist but few have
proven effectiveness, although paracetamol has shown greater
effectiveness than placebo in treating symptoms associated
with upper respiratory tract infection, including sore throat
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(2), headache (3) and fever (4). Cold remedies are available in a
variety of formats, including hot drink and tablet forms.
However, there have been very few clinical studies conducted
to investigate their potential for rapid symptom control.
Whilst capsules and tablets are more convenient for many
customers, hot drink remedies are associated with greater
comfort and they provide active ingredients in solution that
may result in them reaching the bloodstream and being bio-
available faster than tablet formulations. Previous data from a
smaller study of the absorption of paracetamol from a hot
drink formulation (although not specifically designed to esti-
mate pharmacokinetic parameters) indicated that the paracet-
amol from a hot drink was absorbed more quickly than
historically seen with a solid dose formulation (5).
Absorption of paracetamol from the stomach is negligible
but is rapid and significant from the small intestine (6), making
rapid gastric emptying a key approach to reducing the delay
between drug ingestion and onset of symptom control. Fast-
dissolving tablets have been shown to empty from the stomach
more quickly than standard tablets, resulting in earlier ap-
pearance of the drug in the plasma (7–9) and most important-
ly, more rapid pain relief (10). Previous studies using the dual
investigative techniques of gamma scintigraphic imaging com-
bined with concurrent pharmacokinetic (PK) assessment have
shown that the rate of gastric emptying is directly proportional
to the rate of paracetamol absorption (7, 8). Since paraceta-
mol is more soluble in hot water but only sparingly soluble in
cold water, it is hypothesised that presenting paracetamol as a
hot drink will potentially increase the rate of gastric emptying
of the drug as it is already in solution form, negating the
requirement for prior disintegration and dissolution of con-
ventional tablets.
This clinical study was designed to compare the in vivo
behaviour of two paracetamol formulations: one a hot drink
and the other as a standard tablet. Although the hot drink
contained additional ingredients of phenylephrine and ascor-
bic acid (phenylephrine is commonly used as a nasal decon-
gestant to help relieve a blocked nose and ascorbic acid
[Vitamin C] is a common ingredient of cold and flu remedies)
the pharmacology of these ingredients does not suggest that
any effect on the PK of paracetamol is likely.
The simultaneous monitoring of formulation behaviour
using gamma scintigraphy and blood sampling for PK analysis
was utilised to establish the link between formulation disinte-
gration and gastric emptying with resultant serum concentra-
tions of paracetamol. This study fills a knowledge gap where
previously there were no data on the transit rates of hot drink
formulations through the gastrointestinal (GI) tract.
The primary objective of this healthy volunteer study was
to investigate whether paracetamol in a hot drink reaches the
plasma faster than from standard tablets, as determined by the
time to reach a plasma concentration of 0.25 μg/mL (t0.25μg/
mL). Other indicators of the speed of early paracetamol
absorption included AUC0-30, AUC0-60, tmax and Cmax. The
use of these concentrations to determine the PK parameters
was standard and the lower limit of quantification (LLOQ)
was 0.05 μg/mL, so it was proposed that five times the LLOQ
was a robust indicator of paracetamol presence in the blood.
The scintigraphic data provided information on the in vivo fate
of both formulations to allow a correlation to be made be-




Hot drink sachets (Beechams Flu Plus Hot Lemon Sachets)
and standard paracetamol tablets (Panadol Original Tablets)
were supplied by the Clinical Supplies Department,
GlaxoSmithKline Consumer Healthcare UK. Both products
were obtained from a commercially available batch and pack-
aged in commercial packaging. The paracetamol dose was the
same for both the tablet and hot drink formulations
(1,000 mg). Technetium-99 m diethylenetriamine pentaacetic
acid (99mTc-DTPA) was provided by the West of Scotland
Radionuclide Dispensary, Glasgow, UK. Lactose
monohydrate for radiolabelling procedures was obtained
from DMV-Fonterra, The Netherlands.
Formulation Radiolabelling
Hot Drink
A volume of 99mTc-DTPA sufficient to provide approximately
3.8MBq at the target dosing time was added to 150 mL of hot
water. The contents of the sachet were mixed with this
radiolabelled water. The hot drink was allowed to cool suffi-
ciently to be drinkable and was at a temperature between 48
and 50°C at time of dosing.
Standard Paracetamol Tablets
Radiolabelled lactose monohydrate was prepared by mixing
lactose monohydrate with a volume of 99mTc-DTPA sufficient
to provide approximately 1.9 MBq per tablet at the target
dosing time, following drying in hot air. The tablets were
drilled to a fixed depth using a microdrill then filled with the
required dose of radiolabelled lactose monohydrate (approx-
imately 5 mg) and sealed with a small amount of bone cement.
This previously validated radiolabelling methodology has
been used in other scintigraphic studies (11, 12). Unpublished
data from work previously conducted within this clinical cen-
tre confirmed that the complete release of radiolabel correlat-
ed well with complete tablet disintegration.
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This was a phase IV, single centre, open-label, randomised,
two-way crossover study conducted in healthy male volun-
teers. The study was performed according to the protocol and
in accordance with the guidelines of the Declaration of Hel-
sinki and Good Clinical Practice (GCP). The protocol and
relevant study documentation were approved by the Scotland
A Research Ethics Committee. The Administration of Radio-
active Substance Advisory Committee (ARSAC) approved
the radiation dosimetry.
The following study treatments were administered in a
randomisedmanner based on aWilliams Latin Square design:
& Hot drink i.e. 1,000 mg paracetamol, 10 mg phenyleph-
rine and 40 mg ascorbic acid prepared with 150 mL hot
water
& Standard paracetamol tablets i.e. 2×500 mg tablets taken
with 150 mL water at room temperature
To minimise radiation exposure to the subjects, only the
formulation administered on the first dosing occasion was
radiolabelled.
Study Population
A total of 25 healthy male volunteers were enrolled into the
study. They provided written informed consent prior to par-
ticipation in any study-specific investigations and underwent a
screening medical investigation to ensure compliance with
study criteria. The study population included non-smokers
who were in good general health with a body mass index
(BMI) in the range 18.0–29.9 kg/m3.
In addition, it was essential that the subjects did not suffer
from any GI disorders that could impact on the expected
‘normal’ behaviour of the formulations following administra-
tion. As such, subjects with diabetes and current sufferers of
migraine were excluded as they have been found to have
altered gastric emptying (13, 14). Vegetarians were also ex-
cluded as there is evidence that paracetamol absorption is
impaired in this population (15) and due to the standard meals
provided on study assessment days. Female subjects were
excluded due to the need for exposure to radiation and it
has been observed that the menstrual cycle has been associat-
ed with changes in gastric emptying patterns (16). Subjects
with egg allergy were also excluded due to the contents of the
standardised breakfast, and any subjects with a BMI of
≥30 kg/m2 were excluded as shielding caused by bone,
muscle, other organs and soft tissue can attenuate radioactive
counts.
Study Procedures
Eligible subjects attended the study centre on two dosing
occasions. On arrival at the study centre, subjects were
questioned on adherence to study restrictions, which included
pre-breakfast fasting of at least 10 h of which the final 2 h
required abstinence from fluids as well. In the 72 h prior to
dosing, subjects were not allowed any alcohol. They were also
restricted from consuming any caffeine- or xanthine-
containing beverages or foods and undertaking any strenuous
physical activity in the 24 h prior to dosing. Food and fluid
intake on the study days were monitored by study staff and
consisted only of standard meals supplied. Subjects were also
required to abstain from prescribed and over-the-counter
medications for 14 days and 48 h pre-dose, respectively, unless
the medication was approved by a study physician.
At 2 h pre-dose, subjects consumed a standard breakfast
which comprised one scrambled egg, one slice of bacon, one
slice of toast with 15 g butter and 5 g jam, 100 g hash browns
and 200 mL whole milk. The consumption of this meal at this
time was to enable the dosing of study treatments to occur in
the ‘semi-fed’ state, which mimics the normal directions for
usage of analgesic products.
Approximately 15–30 min pre-dose, a blood sample was
taken and, on the first dosing occasion only, external radioac-
tive markers (approximately 0.01 MBq 99mTc) were taped to
the chest and back to enable accurate alignment of sequential
images. At the target dosing time, the subjects were given the
study treatment and were required to complete dosing within
20 s.
The investigator (or designee) collected blood samples from
an indwelling cannula placed in the subject’s arm at the
following times: pre-dosing, then 3, 5, 7, 9, 11, 15, 20, 30,
45, 90, 120 and 180 min post-dosing to allow an assessment of
paracetamol PK. The total blood volume taken at each
timepoint was approximately 4 mL. The actual sample times
were recorded alongside the nominal times on the Case
Report Form (CRF). An acceptable blood sampling time
was considered ± 30 s for up to 11 min, ± 1 min for 15, 20,
30min, then ± 2min from 30min onwards. The total amount
of blood removed during the two treatment visits for PK
analysis was approximate to 104 mL. These blood samples
were centrifuged and plasma fractions removed and frozen
until shipping to a GSK-approved laboratory for analysis.
On the first dosing occasion only, scintigraphic images of
25 s duration each were taken from both anterior and poste-
rior aspects immediately after dosing then every 5 min for a
period of 15 min, then every 15 min to 2 h post-dose, every
20 min to 4 h post-dose and hourly to a maximum of 10 h
post-dose. An acceptable scintigraphic imaging time was
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considered ± 2 min throughout the imaging period. The
images were acquired using a Siemens eCam gamma camera
with a 53.3 cm field of view and fitted with a low energy, high
resolution collimator. Imaging was stopped once complete




Images were collected using the eSoft image acquisition soft-
ware and subsequently analysed using the WebLink software.
The following parameters were derived from the analysis:
& Time to onset and completion of gastric emptying of a hot
drink and standard paracetamol tablets
& Time and site of onset and complete disintegration of
standard paracetamol tablets
Pharmacokinetics
The primary PK variable was the time taken to reach a
plasma paracetamol concentration of 0.25 μg/mL (t0.25). Sec-
ondary PK variables were plasma concentrations of paracet-
amol at each PK sampling point, AUC0-30, AUC0-60, Cmax
and tmax. The PK parameters AUC0-30, AUC0-60, Cmax and
tmax were derived from the observed individual subject drug
concentration versus time data using non-compartmental
methods inWinNonlin® Professional Version 5.0.1 or higher.
Statistics
All statistical analyses were performed using SAS Version 9.2.
Time to onset and completion of gastric emptying were
analysed using an ANOVA model appropriate for a parallel
group design. The time and site of onset and complete disin-
tegration of standard paracetamol tablets were summarised
using descriptive statistics.
The t0.25 and tmax parameters were subjected to a non-
parametric analysis as the assumptions of normality and ho-
mogeneity of variance were not satisfied. A series of Wilcoxon
rank sum tests as described by Hills and Armitage (17) was
conducted and the Hodges-Lehmann estimate of the median
difference between treatments was presented with a corre-
sponding 95% confidence interval (CI) according to the meth-
od described by Hodges and Lehmann (18).
The AUC and Cmax parameters were transformed prior to
analysis using a logarithmic transformation (natural log) and
analysed using an ANOVA model including factors for se-
quence, period and treatment (as fixed effects) and subject
within sequence (as a random effect). The difference in log-
transformed means and associated 95% CIs were back-
transformed (exponentiated). For individual subjects, if AUC
could not be calculated due to an insufficient number of
quantifiable concentrations, then AUC was set to missing for
that subject. If there were fewer than 12 subjects per treatment
group for which AUC could be calculated, then a formal
statistical analysis of AUC was not performed.
Assessment of Safety/Tolerability
Safety was assessed by physical examinations, electrocardio-
gram (ECG), vital signs, laboratory safety evaluations (blood
biochemistry, haematology and urinalysis) and adverse event
(AE) monitoring. Subjects were actively questioned on AEs
before dosing, throughout the study day and at follow-up. AEs
spontaneously reported by subjects were also noted.
RESULTS
Of the 37 subjects screened, 25 were randomised and
completed the study. A flow-chart showing the break-
down of subjects screened, randomised and treated is
shown in Fig. 1.
The subjects had a mean (standard deviation [SD]) age of
30.5 (11.2) years (range: 18–51), a mean (SD) BMI of 24.74
(2.60) kg/m2 and all of the subjects were Caucasian.
The PK and scintigraphy analyses were performed on all
subjects who were randomised, had any post-baseline PK or
scintigraphic measurement, and had pre-dose plasma para-
cetamol concentration values of ≤100 ng/mL. One subject
had a high pre-dose plasma paracetamol concentration value
of 705 ng/mL in the first study period (where he was given the
hot drink) and therefore was excluded from the analysis for
this period only.
Gamma Scintigraphy Results
Example scintigraphic images comparing the gastric emptying
behaviour of the hot drink and the standard tablets are shown
in Fig. 2. At 30 min post-dosing, images clearly indicated that
the hot drink had commenced emptying into the small intes-
tine while the tablets were still relatively intact. Results showed
that the hot drink had a statistically faster onset of
gastric emptying compared with the standard tablets,
as observed from the adjusted mean onset times of
7.86 and 54.23 min, respectively (p<0.0001) (Table I).
However, there was no statistically significant treatment
difference in time to complete gastric emptying, al-
though the completion time was approximately 34 min
faster for subjects dosed with the standard tablet due to
the fact it started to empty later (Table I).
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For all 13 subjects dosed with the radiolabelled standard
tablets, disintegration of tablets commenced and completed in
the stomach. It should be noted that some disintegration of the
tablets would have occurred prior to observation of gastric
emptying of the radiolabel since the radiolabel is centralised in
the tablet core so some non-labelled disintegrated material
will have been released prior to gastric emptying of the
radiolabelled product. However, it has been shown that ad-
ministration of radiolabelled and non-labelled paracetamol
tablets (using the same method of radiolabelling as used in
this study) have similar disintegration rates (8). Onset of disin-
tegration occurred at 43 min (SD=18.0) and completion
occurred at 63 min (SD=24.8) post-dosing.
Pharmacokinetics Results
The mean plasma concentration vs. time profiles for both the
hot drink and standard tablets are shown in Fig. 3. Appearance
of paracetamol in the plasma was more rapid following
administration of the hot drink when compared to the standard
tablets. Tables II and III detail the PK parameters obtained
and derived, as well as the results of the statistical treatments
applied. The results demonstrated that t0.25 was significantly
shorter in subjects dosed with the hot drink compared with
standard paracetamol tablets, with median times to reach t0.25
of 4.59 and 23.14 min, respectively (p=0.0004). The hot drink
had amedian tmax of 1.50 h whichwas significantly shorter than
that of standard tablets (1.99 h) (p-value=0.0058).
AUC0-30 could only be calculated for 6 of the 25 subjects
dosed with standard paracetamol tablets as there was insuffi-
cient quantifiable paracetamol plasma concentrations in the
first 30 min for this treatment group. Since less than 12
subjects had this value calculated, statistical analyses were
not performed for this parameter.
The adjusted geometric means for AUC0-60 for the hot
drink and standard paracetamol tablets were 4668.00 and
1331.17 h*ng/mL respectively, indicating that paracetamol
absorption over the first 60 min post-dose was statistically
significantly greater with a hot drink compared with a stan-
dard paracetamol tablet (p<0.0001). However, Cmax was
significantly higher for the standard paracetamol tablets com-
pared with the hot drink. The adjusted geometric means were
9077.39 and 8061.76 ng/mL, respectively (p=0.0057). These
37 subjects screened 
25 subjects randomised 
AB 
A = Hot drink  
B = Standard tablets 
n=12 
BA 
B = Standard tablets 
A = Hot drink  
n=13 
25 subjects completed the study 
Fig. 1 Subject disposition.
Fig. 2 Example scintigraphic images of gastric emptying behaviour of hot
drink and standard tablets (exact times recorded for each image taken).
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findings may be due to the fact that the hot drink provides a
different bioavailability profile.
Safety/Tolerability
There were no serious AEs (SAEs) or other significant AEs
reported during the study and no subjects were discontinued
due to AEs. The most commonly reported AE was
haematuria in two subjects following the paracetamol hot
drink, which was considered to be unrelated to the study
product in both cases (in both cases mild haematuria was
detected by dipstick and had resolved at the next assessment
with no other associated problems reported). There were no
significant safety issues with regard to vital signs, ECGs, or
safety laboratory tests.
DISCUSSION
Despite the vast array of cold remedies available, there have
been very few clinical studies conducted to investigate their
potential for rapid symptom control. Hot drink remedies are
associated with providing greater comfort possibly because
their intense taste helps stimulate the flow of saliva and mucus
which lubricate and soothe the nose and throat, as well as
helping to clear bacteria and viruses (19). Furthermore, the
active ingredients are available in solution, with paracetamol
being more soluble in hot water but only sparingly so in
cold water, which may result in them reaching the blood-
stream and being bioavailable faster than tablet formula-
tions, thereby resulting in a quicker alleviation of discom-
fort. The premise that a hot drink would result in earlier
paracetamol absorption in comparison to a standard tablet
was based on previously published data that the rate of
appearance of paracetamol in plasma correlated to the rate
of gastric emptying of paracetamol. This is because para-
cetamol absorption depends on the rate of gastric emptying
as it is absorbed in the small intestine rather than the
stomach (20). A drug in solution will be emptied from the
stomach faster (21) hence as the hot remedy is in solution,
gastric emptying will be more rapid and absorption from
the small intestine will occur sooner.
The current study evaluated the formulation behaviour
and drug absorption behaviour of both hot drink and
Table I Times to Onset and Completion of Gastric Emptying
Paracetamol hot drink (N=11) Standard paracetamol tablets (N=13) Difference (adjusted mean) 95% CI (p value)
Adjusted mean (SE) Adjusted mean (SE)
Onset (minutes) 7.86 (3.91) 54.23 (3.60) −46.37 −57.38,−35.35 (<0.0001)
Completion (minutes) 202.59 (16.81) 168.38 (15.46) 34.21 −13.16, 81.58 (0.15)
Fig. 3 Mean paracetamol plasma
concentration vs. time curves (error
bars indicate between subject
variability).
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standard tablet formulations of paracetamol using simulta-
neous gamma scintigraphic imaging and blood sampling for
PK analysis.
The data obtained clearly demonstrated the superiority
of the hot drink over the standard tablet in achieving
faster exposure of paracetamol, as observed from the
median times to reach t0.25. Paracetamol absorption over
the first 60 min post-dose was statistically significantly
greater with a hot drink compared with that of a standard
tablet. Furthermore, tmax was significantly shorter for the
hot drink compared with standard paracetamol tablets.
However, the Cmax observed in the 3-h study period was
significantly higher for the standard paracetamol tablets
compared with the hot drink. However, it is important
to note that total exposure (i.e. AUC0-inf) was not assessed
in this study and therefore it is inappropriate to conclude
that more paracetamol is being delivered with a hot drink
compared to tablet formulation. It could perhaps be ex-
pected that the tablet produces a higher Cmax compared
to the hot drink formulation because the liquid hot drink
is more spread out over the tissue at earlier timepoints
and consequently there is a higher absorption rate per
unit surface area, which results in Cmax concentrations
being higher at earlier timepoints. It is unlikely that tem-
perature has a key effect on Cmax. The clinical significance
of these PK differences on symptom relief remains to be
fully elucidated and future large-scale studies may investi-
gate this finding further, however, based on these results,
it is proposed that a clinical benefit would be noted earlier
following administration of a hot drink compared with a
tablet.
In conjunction with the scintigraphic data that indi-
cated that the time to onset of gastric emptying was
significantly shorter for the hot drink, it can be inferred
that the rapid drug absorption was a consequence of a
more rapid onset of gastric emptying of the hot drink.
Although the hot drink contained additional ingredients
of phenylephrine and ascorbic acid, which might have
been a contributing factor to the PK and gastric emp-
tying differences, the pharmacology of phenylephrine
and ascorbic acid does not suggest that this is likely.
This small-scale pilot study demonstrates interesting initial
results, but further methodologically rigorous studies compris-
ing large, long-term, prospective, randomised clinical trials
are necessary to compare the absorption of different paracet-
amol formulations, together with further elucidation of the
clinical significance of these differences on symptom relief.
CONCLUSION
A hot drink of paracetamol has been shown to achieve faster
and greater early drug absorption in comparison with a stan-
dard tablet formulation. Scintigraphic data supports the pre-
mise that more rapid gastric emptying of the hot drink con-
tributed to the earlier appearance of paracetamol in the
plasma. While comprehensive clinical data is not yet available
to support the hypothesis that administering paracetamol in
the form of a hot drink could result inmore rapid alleviation of
cold symptoms, results of this initial study allude to that
potential.
Table II t0.25 and tmax
Paracetamol hot drink (N=24) Standard paracetamol tablets (N=25) 95% CI (p-value)
Median (range) Median (range)
t0.25 (minutes) 4.59 (3.4, 11.1) 23.14 (6.0, 46.6) −27.31, −15.81 (0.0004)
tmax (hours) 1.50 (0.2, 2.0) 1.99 (0.7, 3.0) −0.85, −0.33 (0.0058)
Table III AUC and Cmax
Paracetamol hot drink adjusted
geometric mean




a 1313.69 (n=24) 232.36 (n=6) N/A (N/A)
AUC0-60 (hr*ng/mL)
b 4668.00 (n=24) 1331.17 (n=20) 2.39, 5.15 (<0.0001)
Cmax (hr*ng/mL)
b 8061.76 (n=24) 9077.39 (n=25) 0.82, 0.96 (0.0057)
a For AUC0-30, unadjusted geometric means are presented
b For AUC0-60 and Cmax, adjusted mean values calculated on log transformed data are back transformed and presented for each treatment group
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